{
    "clinical_study": {
        "@rank": "99237", 
        "arm_group": [
            {
                "arm_group_label": "Oral Viscous Budesonide (OVB)", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will be treated with OVB at a dose of 1 mg twice daily, and they will also be instructed to use a placebo inhaler identical to the fluticasone MDI, with instructions to swallow 4 puffs twice daily."
            }, 
            {
                "arm_group_label": "Active Fluticasone MDI", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will be treated with fluticasone MDI at a dose of 880 mcg twice daily (4 puffs of a 220 mcg inhaler twice daily), and they will also be instructed to take 4 mL twice daily of a placebo slurry of sucralose identical in consistency and taste to the OVB."
            }
        ], 
        "brief_summary": {
            "textblock": "Purpose: To determine whether oral viscous budesonide (OVB) or fluticasone metered dose\n      inhaler (MDI) most effectively treats EoE by improving histologic findings and symptoms,\n      which medication provides a more durable treatment response, and whether biomarkers can\n      predict treatment response.\n\n      Participants: A total of 122 16-80 year old patients with a new diagnosis of eosinophilic\n      esophagitis (EoE)  who are referred for upper endoscopy.\n\n      Procedures: This will be a prospective, randomized, double-blind, double-dummy, clinical\n      trial comparing OVB to fluticasone MDI for treatment of EoE.  This overall study design will\n      generate data for all three Aims"
        }, 
        "brief_title": "Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis", 
        "completion_date": {
            "#text": "July 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Eosinophilic Esophagitis", 
        "condition_browse": {
            "mesh_term": [
                "Esophagitis", 
                "Eosinophilic Esophagitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria are as follows:\n\n          -  Age: 16 - 80 years\n\n          -  New diagnosis of EoE as per consensus guidelines.2  Cases must have symptoms of\n             dysphagia, persistent esophageal eosinophilia (\u2265 15 eosinophils in at least one\n             high-power field) after 8 weeks of treatment with a twice daily proton-pump\n             inhibitor, and other competing causes of esophageal eosinophilia excluded.\n\n        Exclusion criteria are as follows:\n\n          -  Concomitant eosinophilic gastroenteritis\n\n          -  Any corticosteroid exposure within the 4 weeks prior to their baseline endoscopic\n             exam\n\n          -  Requirement for ongoing inhaled corticosteroid use for treatment of asthma or\n             pulmonary disease\n\n          -  Inability to pass a standard 9mm upper endoscope due to esophageal narrowing or\n             stricturing\n\n          -  Previous esophageal surgery\n\n          -  Medical instability that precludes safely performing upper endoscopy\n\n          -  Inability to read or understand English\n\n          -  Pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "122", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02019758", 
            "org_study_id": "13-4047"
        }, 
        "intervention": [
            {
                "arm_group_label": "Oral Viscous Budesonide (OVB)", 
                "intervention_name": "Oral Viscous Budesonide", 
                "intervention_type": "Drug", 
                "other_name": "Pulmicort"
            }, 
            {
                "arm_group_label": "Active Fluticasone MDI", 
                "intervention_name": "Fluticasone MDI", 
                "intervention_type": "Drug", 
                "other_name": "Flovent"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Budesonide", 
                "Fluticasone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 18, 2013", 
        "location": {
            "contact": {
                "email": "jhores@med.unc.edu", 
                "last_name": "Jessica Gebhart, MSHS", 
                "phone": "919-966-4591"
            }, 
            "contact_backup": {
                "last_name": "Susan Moist, MPH", 
                "phone": "919-966-7655"
            }, 
            "facility": {
                "address": {
                    "city": "Chapel Hill", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27599"
                }, 
                "name": "University of North Carolina, Chapel Hill"
            }, 
            "investigator": [
                {
                    "last_name": "Evan S Dellon, MD, MPH", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Nicholas Shaheen, MD, MPH", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis", 
        "other_outcome": [
            {
                "description": "To determine whether baseline immunohistochemical (IHC) staining of esophageal biopsies for major basic protein (MBP), eotaxin-3, and mast cell tryptase (MCT) is associated with histologic response in EoE patients treated with topical corticosteroid therapy.  The mean baseline cellular staining for each biomarker (MBP, eotaxin-3, and MCT) will be compared between the responder and non-responder groups using a two-sample t-test.", 
                "measure": "Baseline immunohistochemical (IHC) staining and histologic response", 
                "safety_issue": "No", 
                "time_frame": "Enrollment (Day 1)"
            }, 
            {
                "description": "To measure the EoE Endoscopic Reference Score (EREFS) based on esophageal findings: esophageal exudates, rings, edema, furrows, and stricture.", 
                "measure": "Endoscopic findings of EoE", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "To measure the levels of histologic response defined as complete responders (< 5 eos/hpf), partial responders (5-14 eos/hpf) and non-responders (\u2265 15 eos/hpf).", 
                "measure": "Levels of histologic response", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "To measure medication compliance by residual OVB slurry left over and the actuation counter on the MDI", 
                "measure": "Medication compliance", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "To determine whether baseline immunohistochemical (IHC) staining of esophageal biopsies for major basic protein (MBP), eotaxin-3, and mast cell tryptase (MCT) is associated with other levels of histologic response (partial response with 5-14 eos/hpf and non-response with \u226515 eos/hpf) in EoE patients treated with topical corticosteroid therapy.", 
                "measure": "Baseline immunohistochemical (IHC) staining and other levels of histologic response", 
                "safety_issue": "No", 
                "time_frame": "Enrollment (Day 1)"
            }
        ], 
        "overall_contact": {
            "email": "jhores@med.unc.edu", 
            "last_name": "Jessica Gebhart, MSHS", 
            "phone": "919-966-4591"
        }, 
        "overall_contact_backup": {
            "last_name": "Susan Moist, MPH", 
            "phone": "919-966-7655"
        }, 
        "overall_official": {
            "affiliation": "University of North Carolina, Chapel Hill", 
            "last_name": "Evan S Dellon, MD, MPH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To determine whether viscous budesonide is more effective than fluticasone MDI for improving post-treatment maximum esophageal eosinophil counts (measured in eosinophils per high powered field (eos/hpf)) in patients with EoE.  The mean post-treatment maximum eosinophil count will be compared between the OVB and MDI groups using a two-sample t-test.  The pre- and post-treatment counts will also be compared within study groups using a paired t-test.", 
                "measure": "Histologic effectiveness of viscous budesonide versus fluticasone MDI", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "To determine whether viscous budesonide is more effective than fluticasone MDI for improving dysphagia (measured by the Daily Symptoms Questionnaire (DSQ)) in patients with EoE.  The mean DSQ scores will be compared between the OVB and MDI groups using a two-sample t-test, and within groups using a paired t-test.", 
                "measure": "Symptomatic effectiveness of viscous budesonide versus fluticasone MDI", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02019758"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To test whether OVB results in less symptomatic recurrence than fluticasone MDI, survival analysis will be performed with the interval between treatment end (week 8) and recurrent symptoms or study end (week 60) as the time of interest.  A Kaplan-Meier curve will be constructed comparing the time until symptom recurrence in both study groups using the log-rank test.", 
                "measure": "Symptom recurrence", 
                "safety_issue": "No", 
                "time_frame": "Symptom recurrence or 1 year after enrollment"
            }, 
            {
                "description": "To test whether OVB results in less histologic recurrence than fluticasone MDI, the proportion of subjects with \u226515 eos/hpf at follow-up endoscopy in each group will be compared using chi-square.", 
                "measure": "Histologic recurrence", 
                "safety_issue": "No", 
                "time_frame": "Symptom recurrence or 1 year after enrollment"
            }
        ], 
        "source": "University of North Carolina, Chapel Hill", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of North Carolina, Chapel Hill", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}